Clinical Cancer Research CR Balducci Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, S.-K.
Right arrow Articles by Carroll, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, S.-K.
Right arrow Articles by Carroll, R. S.
Clinical Cancer Research Vol. 12, 5550-5556, September 15, 2006
© 2006 American Association for Cancer Research

Cancer Therapy: Preclinical

Human Neural Stem Cells Target Experimental Intracranial Medulloblastoma and Deliver a Therapeutic Gene Leading to Tumor Regression

Seung-Ki Kim1, Seung U. Kim2,3, In Ho Park2, Jung Hee Bang2, Karen S. Aboody4, Kyu-Chang Wang5, Byung-Kyu Cho5, Manho Kim6, Lata G. Menon1, Peter M. Black1 and Rona S. Carroll1

Authors' Affiliations: 1 Department of Neurosurgery, Brigham and Women's Hospital and Children's Hospital, Harvard Medical School, Boston, Massachusetts; 2 Brain Disease Research Center, Ajou University, Suwon, Korea; 3 Division of Neurology, UBC Hospital, University of British Columbia, Vancouver, Canada; 4 Divisions of Hematology and Hematopoietic Cell Transplantation and Neurosciences, City of Hope National Medical Center and Beckman Research Institute, Duarte, California; and Departments of 5 Neurosurgery and 6 Neurology, Seoul National University Hospital, Seoul, Korea

Requests for reprints: Rona S. Carroll, Department of Neurosurgery, Brigham and Women's Hospital, 221 Longwood Avenue, Boston, MA 02115. Phone: 617-278-0177; Fax: 617-232-9029; E-mail: rcarroll{at}rics.bwh.harvard.edu.


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 References
 
Purpose: Medulloblastoma, a malignant pediatric brain tumor, is incurable in about one third of patients despite multimodal treatments. In addition, current therapies can lead to long-term disabilities. Based on studies of the extensive tropism of neural stem cells (NSC) toward malignant gliomas and the secretion of growth factors common to glioma and medulloblastoma, we hypothesized that NSCs could target medulloblastoma and be used as a cellular therapeutic delivery system.

Experimental Design: The migratory ability of HB1.F3 cells (an immortalized, clonal human NSC line) to medulloblastoma was studied both in vitro and in vivo. As proof-of-concept, we used HB1.F3 cells engineered to secrete the prodrug activating enzyme cytosine deaminase. We investigated the potential of human NSCs to deliver a therapeutic gene and reduce tumor growth.

Results: The migratory capacity of HB1.F3 cells was confirmed by an in vitro migration assay, and corroborated in vivo by injecting chloromethylbenzamido-Dil–labeled HB1.F3 cells into the hemisphere contralateral to established medulloblastoma in nude mice. In vitro studies showed the therapeutic efficacy of HB1.F3-CD on Daoy cells in coculture experiments. In vitro therapeutic studies were conducted in which animals bearing intracranial medulloblastoma were injected ipsilaterally with HB1.F3-CD cells followed by systemic 5-flourocytosine treatment. Histologic analyses showed that human NSCs migrate to the tumor bed and its boundary, resulting in a 76% reduction of tumor volume in the treatment group (P < 0.01).

Conclusion: These studies show for the first time the potential of human NSCs as an effective delivery system to target and disseminate therapeutic agents to medulloblastoma.

Medulloblastoma is the most common childhood malignant brain tumor. Although multimodal treatments, including radical surgical resection followed by radiation and chemotherapy, have substantially improved the survival rate for this disease, it remains incurable in about one third of patients. These treatments are also toxic and can lead to long-term disabilities (1, 2). The main cause of death is recurrence associated with tumor dissemination, at which point current therapeutic options have little efficacy (3, 4). Consequently, there is substantial need for novel, effective, low-toxicity therapies for children with medulloblastoma.

The discovery of the inherent tumor-tropic properties of neural stem cells (NSC) could serve as a novel adjuvant strategy to current medulloblastoma treatments. Recent studies have shown that NSCs have the capacity to target therapeutic genes to brain tumors, such as malignant glioma (5–13) and melanoma brain metastasis (14). We have expanded these investigations to determine whether NSCs are capable of targeting medulloblastoma in an orthotopic xenograft animal model. Therapeutic proof-of-concept studies were done using cytosine deaminase (CD)–producing NSCs and systemic 5-fluorocytosine (5-FC) prodrug administration. Our results show for the first time the potential of NSCs as an effective delivery system to target and disseminate therapeutic agents to medulloblastoma. This provides a rationale for further evaluation of the NSC-based cellular delivery system for human medulloblastoma.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 References
 
Cell culture. HB1.F3 is an immortalized human NSC (hNSC) line derived from the human fetal brain (ventricular zone) at 15 weeks of gestation by an amphotropic, replication-incompetent retroviral vector containing v-myc (15–18). This is a well-established and well-characterized NSC line that is multipotent, migratory, and nontumorigenic in vivo (12, 15–22). HB1.F3 cells were maintained as adherent cultures in DMEM supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine, and 100 units/mL penicillin, 100 µg/mL streptomycin, 0.25 µg/mL amphotericin B (Invitrogen, Grand Island, NY).

The human medulloblastoma cell line Daoy was obtained from S.L. Pomeroy (Children's Hospital, Boston, MA). The human glioblastoma cell lines U87MG and U251MG and the fibroblast line NIH 3T3 were obtained from the American Type Culture Collection (Manassas, VA). Daoy, U251MG, and NIH 3T3 cells were cultured in DMEM supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine, 2 mmol/L sodium pyruvate, and 100 units/mL penicillin, 100 µg/mL streptomycin, 0.25 µg/mL amphotericin B. U87MG cells were cultured in MEM{alpha} (Invitrogen) supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine, 2 mmol/L nonessential amino acids, 2 mmol/L sodium pyruvate, and 100 units/mL penicillin, 100 µg/mL streptomycin, 0.25 µg/mL amphotericin B. All cells were maintained in humidified atmosphere containing 5% CO2 at 37°C.

In vitro migration assay. The directed migration ability of HB1.F3 to Daoy cells was determined using a modified transwell migration assay. Daoy cells were incubated in serum-free medium for 24 hours, and the resulting conditioned medium was collected and placed in the lower well of fibronectin-coated (Chemicon, Temecula, CA) 10-mm tissue culture Transwell plates (8 µm; Nunc International, Rochester, NY). HB1.F3 cells in serum-free medium (50,000/0.5 mL) were seeded in the upper well of the transwell plates. NIH 3T3 cells were plated as a negative control. Following incubation for 6 hours at 37°C, nonmigrated cells were scraped off the upper side of the filter and the filters were then stained with Three-Step Stain Set (Richard-Allan Scientific, Kalamazoo, MI). All experiments were conducted in quadruplicate. Nuclei of migrated cells were counted in five high-power fields (x200) and the values expressed as the mean ± SE.

In vivo migration assay. To assess the migratory ability of HB1.F3 cells in vivo, the cells were injected intracranially, contralateral to the experimental tumor. Briefly, Swiss nude male mice (n = 8; 6-8 weeks old; Charles River, Wilmington, MA) were anesthetized (100 mg/kg ketamine and 5 mg/kg xylazine) and stereotactically implanted with 120,000 Daoy cells in 3 µL of PBS via a 30-gauge Hamilton syringe into the left forebrain (2.5 mm lateral and 1 mm anterior to bregma, at a 2.5 mm depth from the skull surface). Four weeks after tumor cell implantation, HB1.F3 cells (240,000 in 6 µL PBS) were injected into the right forebrain (2.5 mm lateral and 1 mm anterior to bregma, at a 2.5 mm depth from the skull surface; n = 4). As a control, a group of medulloblastoma-bearing animals (n = 4) were injected with NIH 3T3 cells in the right forebrain using the same stereotactic coordinates. For this study, the ratio of cells tested for their migratory ability (HB1.F3 or NIH 3T3) to tumor cells was 2:1. HB1.F3 or NIH 3T3 cells were labeled with the chloromethylbenzamido-DiI (CM-DiI, Molecular Probes, Eugene, OR) before injection for 30 minutes according to the protocol of the manufacturer. CM-DiI is nondiffusible by virtue of its covalent binding to cellular thiols and has been shown to be particularly suitable for labeling and in vivo tracking of cells for a minimum of 10 weeks (23, 24). Fourteen days after intracranial, contralateral injection of HB1.F3 or NIH 3T3 cells, animals were perfused with 4% paraformaldehyde under deep anesthesia. The brains were harvested, placed in sucrose gradient solution, embedded in optimum cutting temperature compound (Sakura Finetek USA, Torrance, CA), and stored at –80°C. Brains were cryosectioned coronally (10 µm), mounted on slides, and stained with 4',6-diamidino-2-phenylindole per standard protocol. Intracranial distribution of CM-DiI-labeled NSCs was assessed with fluorescent microscopy. All animal studies were carried out in the animal facility at Brigham and Women's Hospital in accordance with federal, local, and institutional guidelines.

Confirmation of chemoattractant ligands and receptors. Recent studies suggest that the brain tumor–targeting behavior of NSCs is mediated by chemoattractant molecules and their respective receptors including stem cell factor (SCF)/c-Kit (25), stromal cell–derived factor 1 (SDF-1)/CXC chemokine receptor 4 (CXCR4; ref. 26) and vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR)-1 and VEGFR2 (22). Therefore, the expression of these chemoattractant ligands and their associated receptors was examined in Daoy and HB1.F3 cells by reverse transcription-PCR.

Total cellular RNA was prepared using the RNeasy Mini Kit protocol (Qiagen, Valencia, CA). Single-stranded cDNA was prepared from 1 µg of total RNA using oligo-p(dT)15 primer following the First Strand cDNA Synthesis Kit for reverse transcription-PCR (avian myeloblastosis virus) protocol (Roche, Indianapolis, IN). cDNA from the reverse transcription reaction was used in the subsequent PCR reactions in the presence of 0.2 µmol/L each of 5' and 3' primers, 2.5 units of Taq polymerase, 1.5 mmol/L MgCl2, 0.2 mmol/L deoxynucleotide mix, and 1x PCR buffer. Touchdown PCR for these chemoattractant factors (ligands and receptors) and ß-actin, a positive control, was carried out for 25 cycles. The reaction products were analyzed on a 2.5% agarose gel stained with ethidium bromide. The sense and antisense primers and the predicted sizes of the reverse transcription-PCR reaction products were as follows: SCF, 5'-ACTTGGATTCTCACTTGCATTT-3' (sense) and 5'-CTTTCTCAGGACTTAATGTTGAAG-3' (antisense; 505 bp); c-Kit, 5'-GCCCACAATAGATTGGTATTT-3' (sense) and 5'-AGCATCTTTACAGCGACAGTC-3' (antisense; 570 bp); SDF-1, 5'-ATGAACGCCAAGGTCGTGGTC-3' (sense) and 5'-GGCTGTTGTGCTTACTTGTTT-3' (antisense; 281 bp); CXCR4, 5'-CTCTCCAAAGGAAAGCGAGGTGGACAT-3' (sense) and 5'-AGACTGTACACTGTAGGTGCTGAAATCA-3' (antisense; 558 bp); VEGF, 5'-AAGCCATCCTGTGTGCCCCTGATG-3' (sense) and 5'-GCTCCTTCCTCCTGCCCGGCTCAC-3' (antisense; 377 bp); VEGFR1, 5'-GCAAGGTGTGACTTTTGTTC-3' (sense) and 5'-AGGATTTCTTCCCCTGTGTA-3' (antisense; 512 bp); VEGFR2, 5'-ACGCTGACATGTACGGTCTAT-3' (sense) and 5'-GCCAAGCTTGTACCATGTGAG-3' (antisense; 438 bp); and ß-actin, 5'-GCCCAGAGCAAGAGAGGCAT-3' (sense) and 5'-GGCCATCTCTTGCTCGAAGT-3' (antisense; 513 bp).

Engineering of HB1.F3-CD. The clonal HB1.F3-CD line was derived from parental HB1.F3 cells. An expression plasmid was constructed with the retroviral pBabePuro backbone to include the E. coli CD cDNA (1.5-kb fragment) transcribed from the long terminal repeat. Vectors were packaged by cotransduction of the CD puro plasmid with the MV12 envelope coding plasmid cDNA into pA317 cells. CD puro retroviral supernatant was used for multiple infections of the HB1.F3 cells. Transduced HB1.F3 cells (HB1.F3-CD) were selected with 3 µg/mL puromycin for 4 weeks.

Successful transduction of HB1.F3-CD cells was confirmed by reverse transcription-PCR. The CD transcript (559 bp) was amplified by touchdown PCR with the following primers: sense, 5'-GCGCGAGTCACCGCCAGCCACACCACGGC-3'; antisense, 5'-GTTTGTAATCGATGGCTTCTGGCTGC-3'. ß-Actin controls confirmed equal RNA loading.

To confirm the bioactivity of CD produced from HB1.F3-CD, the cytotoxic effect of 5-FC and 5-flurouracil (5-FU) on HB1.F3-CD was analyzed by cell viability assay. Sensitivity to 5-FC or 5-FU was also assessed for HB1.F3, Daoy, U87MG, and U251MG cells. For all studies, cells (4 x 103 per well) were plated in 96-well plates (Corning, Inc., Acton, MA). After 24 hours, cells were treated with 5-FC (Sigma-Aldrich, St. Louis, MO) or 5-FU (Sigma-Aldrich) with final concentrations in the range of 0 to 100 µg/mL. Cells were incubated at 37°C for 4 days and quantification of cell viability was done with a colorimetric assay using Cell Counting Kit-8 (Dojindo Molecular Technologies, Gaithersburg, MD). All experiments were conducted in quadruplicate. Viability determination was based on the bioconversion of the tetrazolium compound, 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, into formazan, as determined by absorbance at 450 nm using a multiwell scanning spectrophotometer. Cell viability was expressed as the mean ± SE in percentage of the control viability (=100%).

In addition, the migratory capacity of HB1.F3-CD cells was assessed in vitro and in vivo as described above.

In vitro therapeutic efficacy of HB1.F3-CD. Therapeutic efficacy of HB1.F3-CD cells after 5-FC treatment was analyzed by coculture experiments. Daoy cells (4 x 103 per well) were plated in 96-well plates and experiments were done as follows: on day 1, increasing amounts of HB1.F3 or HB1.F3-CD cells (0, 2 x 103, 4 x 103, 8 x 103, and 16 x 103 per well) were added to the tumor cell cultures; day 2, 5-FC (100 µg/mL) was added to the mixed cell cultures; day 6, quantification of cell viability was done as described above. All experiments were conducted in quadruplicate. Cell viability was expressed as the mean ± SE in percentage of the control viability (=100%).

In vivo therapeutic efficacy of HB1.F3-CD. Animals received stereotactic implantation of Daoy cells (120,000 in 3 µL PBS) into the left forebrain as described above. Two weeks after tumor cell implantation, the animals were randomized into five groups: group 1, treated with ipsilateral intratumoral injection of PBS (8 µL; n = 6); groups 2 and 3, treated with ipsilateral intratumoral injection of 480,000 HB1.F3 cells in 8 µL of PBS (n = 6 for each group); groups 4 and 5, treated with ipsilateral intratumoral injection of 480,000 HB1.F3-CD cells in PBS (n = 6 for each group). In this study, the ratio of stem cells/tumor cells was 4:1. HB1.F3 and HB1.F3-CD were labeled with the CM-DiI cell tracker before injection. One week after hNSC injection, groups 3 and 5 received i.p. injections of 5-FC (500 mg/kg) twice a day for 14 days. Three weeks after the last 5-FC treatment, animals were perfused and the brains harvested and processed as described above. Tissue was stained with 4',6-diamidino-2-phenylindole or H&E per standard protocol. Intracranial distribution of CM-DiI-labeled hNSCs was assessed by fluorescent microscopy. Tumor volumes were estimated using the formula for ellipsoid and expressed as mean ± SE as previously described (27).

Immunohistochemistry was carried out with the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA). Brain sections were fixed in cold acetone. Primary antibody included anti-Ki67 nuclear antigen (1:100; DAKO, Carpinteria, CA) for proliferating cells. Sections were counterstained with hematoxylin, and negative control slides were obtained by omitting the primary antibody. The proliferative index was defined as the percentage of positively stained cells of 100 nuclei from five randomly chosen high-power fields.

Statistics. All of the values were calculated as mean ± SE or were expressed as percentage of control ± SE. Significant differences between assessment of in vitro migration, cell viability, and tumor volume were determined using the Mann-Whitney U test. P < 0.05 was considered significant.


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 References
 
Migratory capacity of hNSCs in vitro. To determine the migratory capacity of hNSCs to medulloblastoma cells, an in vitro transwell migration assay was done. Daoy conditioned medium significantly stimulated the directional migration of HB1.F3 cells (36.8 ± 7.93 cells per high-power field) compared with that of NIH 3T3 cells (4.2 ± 1.30 cells per high-power field; P < 0.05; Fig. 1 ).


Figure 1
View larger version (41K):
[in this window]
[in a new window]
  		Fig. 1. In vitro migration assay. The migratory ability of HB1.F3 or NIH 3T3 cells to Daoy cells was determined using a modified transwell migration assay. Daoy conditioned medium significantly stimulates the directional migration of HB1.F3 cells compared with NIH 3T3 fibroblast cells (36.8 ± 7.93 cells per high-power field for HB1.F3 cells versus 4.2 ± 1.30 cells per high-power field for NIH 3T3 cells; P < 0.05, Mann-Whitney U test). Magnification, x100.

 
Migratory capacity of hNSCs in vivo. To confirm the migratory ability of hNSCs to medulloblastoma in vivo, Daoy cells were implanted into the left hemisphere. Four weeks later, CM-DiI-labeled HB1.F3 cells were injected into the contralateral hemisphere. CM-DiI-labeled HB1.F3 cells were seen migrating across the corpus callosum (Fig. 2A ) and populating medulloblastoma tumor in the opposite hemisphere (Fig. 2B). It should be noted that at the time of HB1.F3 injection (4 weeks after Daoy implantation), the established Daoy tumors were small, but the NSCs were still able to migrate to the tumor site. Very few hNSCs were seen beyond the tumor edge, showing the remarkable migratory capacity of NSCs to the infiltrating tumor cell in the peritumoral normal brain. In contrast, the NIH 3T3 fibroblast cells did not migrate and remained localized at the area of the injection site.


Figure 2
View larger version (45K):
[in this window]
[in a new window]
  		Fig. 2. In vivo migration assay. To assess migratory ability of HB1.F3 cells in vivo, CM-DiI-labeled HB1.F3 cells were injected into the hemisphere contralateral to the tumor cell implantation (Daoy cells). CM-DiI-labeled HB1.F3 cells (red) are seen migrating across the corpus callosum (arrow; 4',6-diamidino-2-phenylindole staining; x40 magnification) in the HB1.F3 injected hemisphere (A) and populating the tumor bed (arrowhead) in the tumor implanted hemisphere (B; x100 magnification).

 
Confirmation of chemoattractant ligands and receptors. The brain tumor–targeting behavior of hNSCs has been reported to be mediated by a multitude of factors, including the SCF/c-Kit (25), SDF-1/CXCR4 (26), and the VEGF/VEGFR1 and VEGFR2 (22) signaling pathways. Using reverse transcription-PCR, the presence of the ligands SCF, SDF-1, and VEGF in Daoy cells, and of their associated receptors c-Kit, CXCR4, VEGFR1, and VEGFR2 in HB1.F3 cells (Fig. 3A ), was confirmed. A ß-actin control confirmed RNA quality.


Figure 3
View larger version (23K):
[in this window]
[in a new window]
  		Fig. 3. The analysis of expression of chemoattractant factors (ligands and receptors) and CD using reverse transcription-PCR. A, the presence of the ligands SCF, SDF-1, and VEGF in Daoy cells, and of their corresponding receptors c-Kit, CXCR4, VEGFR1, and VEGFR2 in HB1.F3 cells, was confirmed and visualized on 2.5% agarose gel. B, the HB1.F3-CD line was derived from HB1.F3 cells by retroviral transduction with E. coli CD. The CD transcript was expressed only in HB1.F3-CD cells, but not in HB1.F3 cells.

 
CD-producing HB1.F3 cells. Expression of the CD transcript in HB1.F3-CD was confirmed by reverse transcription-PCR. The CD transcript was found to be only expressed in HB1.F3-CD cells, but not in the parental HB1.F3 cells (Fig. 3B).

Sensitivity of HB1.F3-CD to 5-FC or 5-FU was assessed and compared with that of HB1.F3, Daoy, U87MG, and U251MG cells. Only HB1.F3-CD cells were sensitive to 5-FC treatment at a concentration of 10 µg/mL (P < 0.05, Fig. 4A ), confirming the enzymatic conversion of prodrug 5-FC to the toxic 5-FU. The growth of the other cell lines was not affected by 5-FC even at a concentration of 100 µg/mL, indicating the lack of expression of CD in these cells. In contrast, all cells lines were sensitive to 5-FU. The highest sensitivity was observed in hNSCs with or without CD transduction, followed by medulloblastoma cells, and lastly in glioblastoma cells in decreasing order (Fig. 4B). A notable and highly significant finding is that medulloblastoma cells are more sensitive to 5-FU than glioblastoma cells such as U87MG and U251MG. For example, Daoy cells (52.7 ± 4.01%) showed a significant decrease in cell viability compared with U87MG (88.8 ± 9.54%) or U251MG (89.2 ± 2.56%) cells at the 0.5 µg/mL 5-FU treatment (P < 0.05).


Figure 4
View larger version (30K):
[in this window]
[in a new window]
  		Fig. 4. The bioactivity of 5-FC and 5-FU was determined by cell viability assay. HB1.F3-CD, HB1.F3, Daoy, U87MG, and U251MG cells (4 x 103 per well each) were plated in 96-well cell plates and sensitivity to 5-FC/5-FU was measured by colorimetric assays with Cell Counting Kit-8. Columns, mean cell viability (percentage of the control viability); bars, SE. A, only HB1.F3-CD cells are sensitive to 5-FC treatment at a concentration of 10 µg/mL 5-FC (P < 0.05, Mann-Whitney U test), confirming the enzymatic conversion of prodrug 5-FC to the toxic 5-FU. The growth of other cells is not affected by 5-FC up to a concentration of 100 µg/mL, indicating the lack of expression of cytosine deaminase in these cells. B, after 5-FU treatment, sensitivity is the highest in human neural stem cells, followed by medulloblastoma cells and glioblastoma cells in decreasing order.

 
The potential for migration of NSCs was not affected by transduction with CD. The migratory pattern of HB1.F3-CD in vitro and in vivo was indistinguishable from that of HB1.F3 cells (Fig. 6A).


Figure 6
View larger version (46K):
[in this window]
[in a new window]
  		Fig. 6. Intracranial distribution and in vivo therapeutic efficacy of HB1.F3-CD. A, HB1.F3-CD were labeled with CM-DiI and injected into the hemisphere contralateral to the tumor cell implantation. HB1.F3-CD cells (red) are observed migrating towards intracranial medulloblastoma (arrowhead) through normal brain parenchyma in a similar pattern as parental cells (4',6-diamidino-2-phenylindole staining; merged image; x100 magnification). B, the majority of CM-DiI-labeled HB1.F3-CD cells, injected intracranially, are located at the border between tumor (arrowhead) and normal parenchyma (4',6-diamidino-2-phenylindole staining; merged image; x100 magnification). Cavity formation (arrow) is more dramatic in areas where the labeled HB1.F3-CD cells are found, suggesting a bystander effect. C, tumor volumes were estimated from histologic analysis. Columns, mean; bars, SE. After systemic treatment with 5-FC, 76% reduction of tumor volume is shown in HB1.F3-CD-treated animals (2.6 ± 1.49 mm3) compared with PBS-treated animals (10.7 ± 6.80 mm3; * P < 0.01, Mann-Whitney U test). D, representative histologic photographs (H&E staining; x1 magnification).

 
In vitro therapeutic efficacy of HB1.F3-CD. To confirm the "bystander effect" of the CD released from the HB1.F3-CD cells, cell viability studies were done in a coculture system. After 5-FC treatment, Daoy cells cultured in the presence of HB1.F3-CD cells, but not the parental HB1.F3 cells, showed significant growth inhibition even when the ratio of HB1.F3-CD cells/tumor cells was as low as 1:2 (P < 0.05; Fig. 5 ). Without 5-FC treatment, Daoy cells cultured with HB1.F3-CD cells showed no growth inhibition. This indicates that HB1.F3-CD cells can convert sufficient amounts of 5-FC to 5-FU to effectively kill Daoy cells in vitro.


Figure 5
View larger version (33K):
[in this window]
[in a new window]
  		Fig. 5. In vitro therapeutic efficacy of HB1.F3-CD. Therapeutic efficacy of HB1.F3-CD cells after 5-FC treatment was analyzed by coculture experiments. Daoy cells (4 x 103 per well) were plated in 96-well plates. After 24 hours, increasing amounts of HB1.F3 or HB1.F3-CD cells (0, 2 x 103, 4 x 103, 8 x 103, and 16 x 103 per well) were added to the tumor cell cultures. After 5-FC (100 µg/mL) treatment, cell viability was measured by colorimetric assays with Cell Counting Kit-8. Columns, mean percentage of the control viability; bars, SE. Daoy cells cultured in the presence of HB1.F3-CD cells, but not HB1.F3 cells, show significant growth inhibition after 5-FC treatment, even when the ratio of HB1.F3-CD cells/tumor cells is as low as 1:2 (P < 0.05, Mann-Whitney U test). Without 5-FC treatment, Daoy cells cultured with HB1.F3-CD cells show no growth inhibition.

 
In vivo therapeutic efficacy of HB1.F3-CD. To assess the therapeutic efficacy of HB1.F3-CD in medulloblastoma animal models, we injected CM-DiI-labeled HB1.F3-CD cells into tumor-bearing animals. The distribution of HB1.F3-CD cells and tumor volumes were determined on harvested brain tissue 3 weeks after the last 5-FC treatment. In vivo studies showed that the majority of intracranially injected CM-DiI-labeled HB1.F3-CD cells localized to the tumor bed and the tumor-normal parenchyma interface (Fig. 6B ).

Histologic analysis showed a 76% reduction of tumor volume in the brains of 5-FC-treated HB1.F3-CD animals (2.6 ± 1.49 mm3) compared with PBS-treated control animals (10.7 ± 6.80 mm3; P < 0.01; Fig. 6C and D) and all other control groups. We could not detect any abnormalities in the parenchyma surrounding the tumor in treated animals. The proliferative index revealed no significant differences among the groups.


   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
References
 
The focus of this study is to explore the migratory capacity and therapeutic potential of hNSCs in experimental medulloblastoma. We have previously reported the inherent migratory, tumor-tropic, and therapeutic properties of NSCs (C17.2 and HB1.F3) to intracranial glioblastomas (5, 12). In this study, we have chosen to use human HB1.F3 NSCs as it is a well-established and well-characterized human stem cell line (12, 15–22). No signs of local or systemic toxicity in HB1.F3 and HB1.F3-CD treated groups were observed although the therapeutic effects were assessed 6 weeks after hNSC injection.

The in vitro and in vivo studies clearly show for the first time the ability of NSCs to target medulloblastoma, indicating that the tumor tropism of NSCs is not limited to gliomas (14). Furthermore, migration of HB1.F3 was not affected by the CD transduction. To better define the crosstalk between medulloblastoma and hNSCs, we investigated the signals that have been shown to modulate the brain tumor tropism of NSCs, such as SCF/c-Kit (25), SDF-1/CXCR4 (26), and VEGF/VEGFR1 and VEGFR2 (22). Our study documented the presence of chemoattractant factors (ligands in medulloblastoma and receptors in hNSCs), which may allow them to communicate with each other and facilitate the migration we observed.

After confirmation of the tropism of hNSCs for medulloblastoma, we tested their therapeutic potential using the CD enzyme/5-FC prodrug system. CD is a bacterial enzyme that converts the nontoxic prodrug 5-FC to the cytotoxic drug 5-FU, a nucleotide analogue that disrupts DNA synthesis in proliferating cells (28). Because mammalian cells do not express significant amounts of CD, as shown in the present study, 5-FC is nontoxic at concentrations that result in strong antimicrobial activity. Tumor cells transfected with the E. coli CD gene become selectively sensitive to the toxic effects of 5-FC; e.g., expression of this enzyme in glioma cells confers their lethal sensitivity to systemically administration of 5-FC (29). In addition, this enzyme/prodrug system has a bystander effect (30, 31), shown by the death of unmodified tumor cells adjacent to genetically modified cells. NSCs engineered to express a suicide gene such as CD are a particularly good choice because they can generate agents that kill tumor cells as well as result in self-elimination if the NSCs start dividing in vivo. Although HB1.F3 cells have proved to be a non-tumor-producing line in vivo model (12, 15–22), there is possibility of integration of NSCs into the stroma of brain tumors. Recently, more studies of neurogenesis have focused on modulation of endogenous precursors, rather than in vitro propagation of cell lines (32).

Our group and others have shown that NSCs transduced with the CD gene retain their tumor tracking properties and are therapeutically effective for malignant gliomas in animal models (5, 6). To our knowledge, these data are the first to show therapeutic efficacy of this hNSC-CD/5-FC system in a medulloblastoma model; the systemic administration of 5-FC in combination with CD-expressing hNSCs resulted in a 76% reduction in intracranial medulloblastoma tumor volume in nude mice.

Although there was a significant tumor volume reduction induced by this therapy, the proliferative index of the remaining tumor was still high. As the therapeutic benefit from one-time drug delivery may be short-lived as the tumor regrows, additional cycles of HB1.F3-CD and 5-FC therapy can be given to eradicate the cancer cells not removed by the first wave of therapy. Alternatively, NSCs can be engineered with other potentially beneficial therapeutic genes (differentiating agents, immune-enhancing agents, apoptosis-promoting agents, antiangiogenic agents, etc.), which can be given in combination with HB1.F3-CDs or sequentially.

Although systemic 5-FU is not routinely used in the clinical management of brain tumors, as it does not cross the blood-brain barrier, we clearly show that medulloblastoma is sensitive to 5-FU, even more so than glioblastoma. The selective activation of prodrug in tumor tissues by exogenous enzyme for cancer therapy has been accomplished by several ways, including gene-directed enzyme prodrug therapy, virus-directed enzyme prodrug therapy, and antibody-directed enzyme prodrug therapy (33). Our cell-directed enzyme prodrug therapy with NSCs is potentially more flexible than previous methods because of the tumor-tropic capacity of NSCs. Because of an impressive bystander effect, as little as 2% of the tumor mass containing CD-expressing cells may generate significant oncolysis (31). This unique property increases the likelihood of achieving therapeutic efficacy. When cell-directed enzyme prodrug therapy is applied clinically, the interval between enzyme and prodrug administrations should be optimized so that CD/5-FC system could work after NSCs localize to tumor site to avoid systemic toxicity.

In the clinical setting, NSC therapy could be used in conjunction with standard therapies. Especially in the case of recurrence with tumor dissemination in the subarachnoid space, NSCs can be grafted into tumor resection cavity to target residual invading and disseminating tumor cells. Furthermore, based on our study, the same approach can be exploited using other sources of stem cells and engineered to deliver other antitumor agents for medulloblastoma therapies.

In conclusion, this study indicates that hNSCs have migratory capacity and tropism for medulloblastoma. Furthermore, they can be genetically modified ex vivo to express genes that have therapeutic efficacy against human medulloblastoma. These results suggest a potential role of hNSCs as a targeted, therapeutic delivery vehicle for human medulloblastoma.


   Footnotes
 
Grant support: NIH and Seoul National University Hospital Research Fund no. 03-2002-092 (B-K. Cho), Korea Science and Engineering Foundation-Science Research Center, Ajou University Brain Disease Center (S.U. Kim), Hagerty Fund (P.M. Black), and Korea Research Foundation Grant no. KRF-2006-312-E00117 (S-K. Kim).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 11/15/05; revised 5/ 9/06; accepted 6/ 8/06.


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

  1. Packer RJ, Cogen P, Vezina G, Rorke LB. Medulloblastoma: clinical and biologic aspects. Neuro-oncol 1999;1:232–50.[Abstract]
  2. Yang SY, Wang KC, Cho BK, et al. Radiation-induced cerebellar glioblastoma at the site of a treated medulloblastoma: case report. J Neurosurg 2005;102:417–22.[Medline]
  3. Graham ML, Herndon JE II, Casey JR, et al. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 1997;15:1814–23.[Abstract/Free Full Text]
  4. Patrice SJ, Tarbell NJ, Goumnerova LC, Shrieve DC, Black PM, Loeffler JS. Results of radiosurgery in the management of recurrent and residual medulloblastoma. Pediatr Neurosurg 1995;22:197–203.[Medline]
  5. Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A 2000;97:12846–51.[Abstract/Free Full Text]
  6. Barresi V, Belluardo N, Sipione S, Mudo G, Cattaneo E, Condorelli DF. Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy. Cancer Gene Ther 2003;10:396–402.[CrossRef][Medline]
  7. Benedetti S, Pirola B, Pollo B, et al. Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 2000;6:447–50.[CrossRef][Medline]
  8. Brown AB, Yang W, Schmidt NO, et al. Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Hum Gene Ther 2003;14:1777–85.[CrossRef][Medline]
  9. Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL, Yu JS. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res 2002;62:5657–63.[Abstract/Free Full Text]
  10. Ehtesham M, Kabos P, Gutierrez MA, et al. Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2002;62:7170–4.[Abstract/Free Full Text]
  11. Herrlinger U, Woiciechowski C, Sena-Esteves M, et al. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. Mol Ther 2000;1:347–57.[CrossRef][Medline]
  12. Kim SK, Cargioli TG, Machluf M, et al. PEX-producing human neural stem cells inhibit tumor growth in a mouse glioma model. Clin Cancer Res 2005;11:5965–70.[Abstract/Free Full Text]
  13. Shah K, Bureau E, Kim DE, et al. Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Ann Neurol 2005;57:34–41.[CrossRef][Medline]
  14. Aboody KS, Najbauer J, Schmidt NO, et al. Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. Neuro-oncol 2006;8:119–26.[Abstract/Free Full Text]
  15. Cho T, Bae JH, Choi HB, et al. Human neural stem cells: electrophysiological properties of voltage-gated ion channels. Neuroreport 2002;13:1447–52.[CrossRef][Medline]
  16. Flax JD, Aurora S, Yang C, et al. Engraftable human neural stem cells respond to developmental cues, replace neurons, and express foreign genes. Nat Biotechnol 1998;16:1033–9.[CrossRef][Medline]
  17. Kim SU. Human neural stem cells genetically modified for brain repair in neurological disorders. Neuropathology 2004;24:159–71.[CrossRef][Medline]
  18. Ourednik V, Ourednik J, Flax JD, et al. Segregation of human neural stem cells in the developing primate forebrain. Science 2001;293:1820–4.[Abstract/Free Full Text]
  19. Chu K, Kim M, Chae SH, et al. Distribution and in situ proliferation patterns of intravenously injected immortalized human neural stem-like cells in rats with focal cerebral ischemia. Neurosci Res 2004;50:459–65.[CrossRef][Medline]
  20. Chu K, Kim M, Jeong SW, Kim SU, Yoon BW. Human neural stem cells can migrate, differentiate, and integrate after intravenous transplantation in adult rats with transient forebrain ischemia. Neurosci Lett 2003;343:129–33.[CrossRef][Medline]
  21. Jeong SW, Chu K, Jung KH, Kim SU, Kim M, Roh JK. Human neural stem cell transplantation promotes functional recovery in rats with experimental intracerebral hemorrhage. Stroke 2003;34:2258–63.[Abstract/Free Full Text]
  22. Schmidt NO, Przylecki W, Yang W, et al. Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor. Neoplasia 2005;7:623–9.[CrossRef][Medline]
  23. Fraser SE. Iontophoretic dye labeling of embryonic cells. Methods Cell Biol 1996;51:147–60.[Medline]
  24. Imitola J, Raddassi K, Park KI, et al. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1{alpha}/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci U S A 2004;101:18117–22.[Abstract/Free Full Text]
  25. Sun L, Lee J, Fine HA. Neuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury. J Clin Invest 2004;113:1364–74.[CrossRef][Medline]
  26. Ehtesham M, Yuan X, Kabos P, et al. Glioma tropic neural stem cells consist of astrocytic precursors and their migratory capacity is mediated by CXCR4. Neoplasia 2004;6:287–93.[CrossRef][Medline]
  27. Schmidt KF, Ziu M, Schmidt NO, et al. Volume reconstruction techniques improve the correlation between histological and in vivo tumor volume measurements in mouse models of human gliomas. J Neurooncol 2004;68:207–15.[CrossRef][Medline]
  28. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci U S A 1992;89:33–7.[Abstract/Free Full Text]
  29. Miller CR, Williams CR, Buchsbaum DJ, Gillespie GY. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res 2002;62:773–80.[Abstract/Free Full Text]
  30. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53:5274–83.[Abstract/Free Full Text]
  31. Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A 1994;91:8302–6.[Abstract/Free Full Text]
  32. Goldman S. Stem and progenitor cell-based therapy of the human central nervous system. Nat Biotechnol 2005;23:862–71.[CrossRef][Medline]
  33. Xu G, McLeod HL. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res 2001;7:3314–24.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Mol Cancer ResHome page
D. Zhao, J. Najbauer, E. Garcia, M. Z. Metz, M. Gutova, C. A. Glackin, S. U. Kim, and K. S. Aboody
Neural Stem Cell Tropism to Glioma: Critical Role of Tumor Hypoxia
Mol. Cancer Res., December 1, 2008; 6(12): 1819 - 1829.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Hingtgen, X. Ren, E. Terwilliger, M. Classon, R. Weissleder, and K. Shah
Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide
Mol. Cancer Ther., November 1, 2008; 7(11): 3575 - 3585.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
S. E. Kendall, J. Najbauer, H. F. Johnston, M. Z. Metz, S. Li, M. Bowers, E. Garcia, S. U. Kim, M. E. Barish, K. S. Aboody, et al.
Neural Stem Cell Targeting of Glioma Is Dependent on Phosphoinositide 3-Kinase Signaling
Stem Cells, June 1, 2008; 26(6): 1575 - 1586.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
M. Gutova, J. Najbauer, R. T. Frank, S. E. Kendall, A. Gevorgyan, M. Z. Metz, M. Guevorkian, M. Edmiston, D. Zhao, C. A. Glackin, et al.
Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor Mediate Human Stem Cell Tropism to Malignant Solid Tumors
Stem Cells, June 1, 2008; 26(6): 1406 - 1413.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Kucerova, V. Altanerova, M. Matuskova, S. Tyciakova, and C. Altaner
Adipose Tissue-Derived Human Mesenchymal Stem Cells Mediated Prodrug Cancer Gene Therapy
Cancer Res., July 1, 2007; 67(13): 6304 - 6313.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, S.-K.
Right arrow Articles by Carroll, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, S.-K.
Right arrow Articles by Carroll, R. S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online